Results from VENTURE Phase 2 Study of
Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral
VK2735 in Healthy Subjects to be Presented
SAN
DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
that clinical data from the company's VK2735 obesity program will
be highlighted in two poster presentations at
ObesityWeek® 2024, the annual meeting of the Obesity
Society. VK2735 is a dual agonist of the glucagon-like
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP) receptors being developed for the potential treatment of
various metabolic disorders. Viking is evaluating both
subcutaneous and oral formulations of VK2735 in clinical
trials. ObesityWeek 2024 is being held November 3-6, 2024, in San Antonio, Texas.
One presentation will summarize results from the company's Phase
2 VENTURE clinical trial, which evaluated 13 weeks of weekly
treatment with a subcutaneous formulation of VK2735 in obese
subjects. A second presentation will highlight results from
the company's Phase 1 multiple ascending dose (MAD) clinical trial
of an oral tablet formulation of VK2735 dosed daily for 28
days.
Details of the presentations are as follows:
Poster Presentation #018:
Title: Results from the 13-Week VENTURE Phase 2
Study of the GLP-1/GIP Co-Agonist VK2735 in Obese Subjects
Presenting Author: Joel Neutel, M.D., Orange County
Research Center
Date/Time: Sunday, November 3,
2024, 7:30 – 8:30 p.m. Central
Time
Location: Exhibit Hall 4B of the Henry B. Gonzalez Convention
Center
Poster Presentation #017:
Title: First-in-Human Study of an Oral Formulation
of the GLP-1/GIP Co-Agonist VK2735 in Healthy Adults
Presenting Author: Joel Neutel, M.D., Orange County
Research Center
Date/Time: Sunday, November 3,
2024, 7:30 – 8:30 p.m. Central
Time
Location: Exhibit Hall 4B
of the Henry B. Gonzalez Convention Center
About GLP-1 and Dual GLP-1/GIP Agonists
Activation of the glucagon-like peptide 1 (GLP-1) receptor has
been shown to decrease glucose, reduce appetite, lower body weight,
and improve insulin sensitivity in patients with type 2 diabetes,
obesity, or both. Semaglutide is a GLP-1 receptor agonist that has
been approved by the U.S. Food and Drug Administration and is
currently marketed in various dosage strengths and forms as
Ozempic®, Rybelsus®, and Wegovy®.
More recently, research efforts have explored the potential
co-activation of the glucose-dependent insulinotropic peptide (GIP)
receptor as a means of enhancing the therapeutic benefits of GLP-1
receptor activation. Tirzepatide is a dual GLP-1/GIP receptor
agonist that has been approved by the U.S. Food and Drug
Administration and is currently marketed in various dosage
strengths and forms as Mounjaro® and
Zepbound®.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders, with three compounds currently in clinical
trials. Viking's research and development activities leverage
its expertise in metabolism to develop innovative therapeutics
designed to improve patients' lives. Viking's clinical
programs include VK2735, a novel dual agonist of the glucagon-like
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP) receptors for the potential treatment of various metabolic
disorders. Data from a Phase 1 and a Phase 2 trial evaluating
VK2735 (dosed subcutaneously) for metabolic disorders demonstrated
an encouraging safety and tolerability profile as well as positive
signs of clinical benefit. Concurrently, the company is evaluating
an oral formulation of VK2735 in a Phase 1 trial. Viking is also
developing VK2809, a novel, orally available, small molecule
selective thyroid hormone receptor beta agonist for the treatment
of lipid and metabolic disorders. The compound successfully
achieved both the primary and secondary endpoints in a recently
completed Phase 2b study for the treatment of
biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial
for the treatment of non-alcoholic fatty liver disease (NAFLD) and
elevated LDL-C, patients who received VK2809 demonstrated
statistically significant reductions in LDL-C and liver fat content
compared with patients who received placebo. The company's
newest program is evaluating a series of internally developed dual
amylin and calcitonin receptor agonists (or DACRAs) for the
treatment of obesity and other metabolic disorders. In the
rare disease space, Viking is developing VK0214, a novel, orally
available, small molecule selective thyroid hormone receptor beta
agonist for the potential treatment of X-linked
adrenoleukodystrophy (X-ALD). In a
Phase 1b clinical trial in patients with the
adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be
safe and well-tolerated, while driving significant reductions in
plasma levels of very long-chain fatty acids (VLCFAs) and other
lipids, as compared to placebo.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-highlight-clinical-data-from-vk2735-obesity-program-in-presentations-at-obesityweek-2024-302288898.html
SOURCE Viking Therapeutics, Inc.